Table 1.
Characteristics of patients with small intestine adenocarcinoma.
| Characteristics | Total |
2004–2010 |
2011–2014 |
P value |
|---|---|---|---|---|
| 1516 (100%) | 908 (60%) | 608 (40%) | ||
| Age (years) | ||||
| Mean (SD) | 63 (53, 73) | 63 (53, 73) | 63 (54, 72) | 0.625 |
| <50 | 260 (17%) | 152 (17%) | 108 (18%) | 0.125 |
| 50–75 | 995 (66%) | 585 (66%) | 410 (67%) | |
| >75 | 261 (17%) | 171 (19%) | 90 (15%) | |
| Gender | 0.375 | |||
| Male | 828 (55%) | 487 (54%) | 341 (56%) | |
| Female | 688 (45%) | 421 (46%) | 267 (44%) | |
| Race | 0.261 | |||
| White | 1151 (76%) | 701 (77%) | 450 (74%) | |
| Black | 260 (17%) | 144 (16%) | 116 (19%) | |
| Others | 105 (7%) | 63 (7%) | 42 (7%) | |
| Location | 0.168 | |||
| Duodenum | 772 (51%) | 451 (50%) | 321 (53%) | |
| Jejunum | 396 (26%) | 255 (28%) | 141 (23%) | |
| Ileum | 325 (21%) | 187 (21%) | 138 (23%) | |
| Small intestine, not specified | 23 (2%) | 15 (2%) | 8 (1%) | |
| 8th TNM stage | 0.084 | |||
| I | 107 (7%) | 61 (7%) | 46 (8%) | |
| IIA | 305 (20%) | 192 (21%) | 113 (19%) | |
| IIB | 200 (13%) | 104 (11%) | 96 (16%) | |
| IIIA | 413 (27%) | 256 (28%) | 157 (26%) | |
| IIIB | 263 (17%) | 150 (17%) | 113 (19%) | |
| IV | 228 (15%) | 145 (16%) | 83 (14%) | |
| 8th T stage | 0.062 | |||
| T1 | 47 (2%) | 31 (3%) | 16 (2%) | |
| T2 | 99 (7%) | 52 (6%) | 47 (8%) | |
| T3 | 679 (45%) | 429 (47%) | 250 (41%) | |
| T4 | 691 (46%) | 396 (44%) | 295 (49%) | |
| 8th N stage | 0.099 | |||
| N0 | 660 (44%) | 387 (43%) | 273 (45%) | |
| N1 | 498 (33%) | 317 (35%) | 181 (30%) | |
| N2 | 358 (24%) | 204 (22%) | 154 (25%) | |
| 8th M stage | 0.244 | |||
| M0 | 1288 (85%) | 763 (84%) | 525 (86%) | |
| M1 | 228 (15%) | 145 (16%) | 83 (14%) | |
| Grade | 0.057 | |||
| G1/G2 | 927 (61%) | 537 (59%) | 390 (64%) | |
| G3/G4 | 589 (39%) | 371 (41%) | 218 (36%) | |
| Histology | 0.390 | |||
| Conventional adenocarcinoma | 1330 (88%) | 793 (87%) | 537 (88%) | |
| Mucinous adenocarcinoma | 128 (8%) | 83 (9%) | 45 (7%) | |
| Signet ring cell carcinoma | 58 (4%) | 32 (4%) | 26 (4%) | |
| Examined lymph nodes | <0.001 | |||
| ≤16 | 1012 (67%) | 641 (71%) | 371 (61%) | |
| >16 | 504 (33%) | 267 (29%) | 237 (39%) | |
| Positive lymph nodes | 1 (0, 3) | 1 (0, 3) | 1 (0, 4) | 0.735 |
| Tumor size | 0.052 | |||
| ≤5 cm | 1012 (67%) | 641 (71%) | 371 (61%) | |
| >5 cm | 504 (33%) | 267 (29%) | 237 (39%) | |
| Median follow-up time (months) | 25.0 | 40.0 | 16.0 | <0.001 |